Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mansfield

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
Annals of Surgical Oncology|February 19, 2026
Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.
The Lancet. Oncology|August 8, 2020
Hereditary diffuse gastric cancer: updated clinical practice guidelinesVanessa R Blair, Maybelle McLeod, Fátima Carneiro, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
Annals of Surgical Oncology|February 19, 2026
Patient-Reported Symptom Recovery After Upper Gastrointestinal Cancer Surgery: A Prospective Study Using the MDASI-UGI-SurgKoichi Tomita, Paula M Smith, Maho Takayama, et al.
Cancer Discovery|July 15, 2021
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal MesotheliomaKanwal Raghav, Suyu Liu, Michael J Overman, et al.
The Lancet. Oncology|August 8, 2020
Hereditary diffuse gastric cancer: updated clinical practice guidelinesVanessa R Blair, Maybelle McLeod, Fátima Carneiro, et al.
Pageof 20